Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

European Heart Journal

Volumn 26, Issue 6, 2005, Pages 567-575

  Claeys, Marc J ^a   Van Der Planken, Marc G ^a   Bosmans, Johan M ^a   Michiels, Jan J ^a   Vertessen, Francine ^a   Van Der Goten, Peter ^a   Wuyts, Floris L ^a   Vrints, Chris J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Creatinine kinase; Glycoprotein; Platelets; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; BLOOD SAMPLING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG EFFECT; ELECTIVE SURGERY; ENZYME RELEASE; FEMALE; HEART DEATH; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

AGED; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOENZYMES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREMEDICATION; RECURRENCE; STENTS; SURVIVAL RATE; THROMBOSIS; TICLOPIDINE; TROPONIN T;

EID: 16244376473     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi071     Document Type: Conference Paper

References (25)

1. Haude M, Erbel R, Straub U et al. Short and long term results after intracoronary stenting in human coronary arteries: monocentre experience with the balloon-expandable Palmaz-Schatz stent. Br Heart J 1991;66:337-345.
2. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [see comments]. N Engl J Med 1996; 334:1084-1089.
3. Bertrand ME, Rupprecht HJ, Urban P et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102:624-629.
4. Claeys MJ. Antiplatelet therapy for elective coronary stenting: a moving target. Semin Vasc Medi 2003;3:415-418.
5. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
6. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
7. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
8. Steinhubl SR, Lauer MS, Mukherjee DP et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998;32:1366-1370.
9. Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
10. Claeys MJ, Van Der Planken MG, Michiels JJ et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis 2002;13:283-288.
11. Van Der Planken MG, Claeys MJ, Vertessen FJ et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA·100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003;111: 159-164.
12. Smith SC, Jr, Dove JT, Jacobs AK et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37: 2215-2239.
13. Gibson CM, Cannon CP, Daley WL et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879-888.
14. Brener SJ, Ellis SG, Schneider J et al. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23:869-876.
15. Gawaz M, Neumann FJ, Ott I et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94:279-285.
16. Cadroy Y, Bossavy JP, Thalamas C et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823-2828.
17. Bonz AW, Lengenfelder B, Strotmann J et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002;40:662-668.
18. Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004;350:232-238.
19. Muller I, Seyfarth M, Rudiger S et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92-93.
20. Ricciardi MJ, Wu E, Davidson CJ et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
21. Blankenship JC, Tasissa G, O'Shea JC et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001;38:653-658.
22. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
23. Roffi M, Mukherjee D, Chew DP et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002;106:3063-3067.
24. Herrmann J, Lerman A, Baumgart D et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-2183.
25. Baim DS, Wahr D, George B et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105:1285-1290.